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Abstract: CYP102A1 (BM3) is a catalytically self-sufficient flavocytochrome fusion protein isolated
from Bacillus megaterium, which displays similar metabolic capabilities to many drug-metabolizing
human P450 isoforms. BM3′s high catalytic efficiency, ease of production and malleable active
site makes the enzyme a desirable tool in the production of small molecule metabolites, especially
for compounds that exhibit drug-like chemical properties. The engineering of select key residues
within the BM3 active site vastly expands the catalytic repertoire, generating variants which can
perform a range of modifications. This provides an attractive alternative route to the production of
valuable compounds that are often laborious to synthesize via traditional organic means. Extensive
studies have been conducted with the aim of engineering BM3 to expand metabolite production
towards a comprehensive range of drug-like compounds, with many key examples found both in the
literature and in the wider industrial bioproduction setting of desirable oxy-metabolite production
by both wild-type BM3 and related variants. This review covers the past and current research on
the engineering of BM3 to produce drug metabolites and highlights its crucial role in the future of
biosynthetic pharmaceutical production.
Keywords: CYP102A1; P450 BM3; drug metabolism; cytochromes P450; P450 engineering; biocatalysis
1. Context and Introduction to BM3
Most commercially available pharmaceuticals are produced via traditional organic
synthesis routes. However, this approach is limited by the scope of traditional chemical
catalysts that often yield predictably similar products. This leads to a difficulty in the syn-
thesis of compounds that exhibit enantioselectivity and structural motifs such as specific
hydroxyl groups. There is also a commercial interest in reducing manufacturing costs. Due
to these factors, efforts are being made to move future pharmaceutical synthesis towards
alternative routes of production that focus on sustainability and cost efficiency [1]. One area
of current interest is biosynthetic manufacture, which harnesses bacterial cells and enzymes
for metabolite production as an organic synthesis replacement. These alternatives are both
relatively cheap and easy to produce. Additionally, enzymes often have the added advan-
tage of exhibiting higher yields and selectivity towards native small molecule substrates.
Of particular interest are the cytochrome P450 (P450 or CYP) enzyme superfamily. These
heme enzymes are primarily monooxygenases that are found in most living organisms
and share similarities in their characteristic ‘P450′ fold and the highly conserved, cysteine
thiolate-coordinated heme prosthetic group [2].
P450s perform oxidations on a diverse range of organic small molecule substrates and
have many physiological roles in biosynthetic and detoxification pathways [3].
A major biotransformation that is typical of the P450 superfamily is the hydroxylation
Int. J. Mol. Sci. 2021, 22, 11380. https://doi.org/10.3390/ijms222111380 https://www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2021, 22, 11380 2 of 23
of carbon–hydrogen bonds via the insertion of an oxygen atom, yielding a hydroxylated
metabolite and a molecule of water. The metabolism of substrates is achieved by a complex
multi-step catalytic cycle via the heme prosthetic group. In this mechanism, the docking of
the substrate and the removal of the distal water ligand of the heme iron triggers a series
of transient changes in the heme iron state. These changes involve the transfer of two
electrons, a proton and the binding of dioxygen. In the canonical catalytic cycle this leads to
the eventual abstraction of a substrate proton which then rebounds to produce an oxidized
metabolite [4]. Other P450-catalyzed biotransformations include (but are not limited to)
heteroatom oxygenations, dealkylations, epoxidations, ring cleavages, dehydrogenations
and sulfoxidations [3]. Human P450s have numerous physiological functions and are
widely known for their role in xenobiotic metabolism, typically adding polar functional
groups, facilitating an excretion of the product [5]. Since the discovery of P450s there has
been an interest in utilizing the P450 superfamily as an alternative route for the synthesis
of valuable small molecules, as their mechanistic capabilities can yield oxy-metabolites
that are laborious to synthesize via traditional organic synthesis routes. The main drug-
metabolizing human P450s exhibits promiscuity and wide substrate profiles. However,
due to their eukaryotic nature and N-terminal membrane anchor they can be difficult to
express in bacterial hosts that are typically used for biocatalytic cascades. Furthermore,
their functioning requires the use of a reductase partner to supply the electron necessary for
catalysis. In general, human P450s are catalytically slow. Therefore, there is an advantage to
be gained from utilizing soluble bacterial P450s as biocatalysts for metabolite production.
P450 BM3
A bacterial P450 that has been explored extensively for metabolite production capa-
bilities is the natural fusion protein, flavocytochrome P450 BM3 (BM3, CYP102A1) [6–8].
BM3 was isolated in the early 1970s from the soil bacterium, Bacillus megaterium (the third
P450 to be extracted from B. megaterium), and was identified as a fatty acid hydroxylase
that did not require the addition of an independent redox partner [6,7]. Structural studies
reveal that BM3 is a 119.5 kilodalton (kDa) single polypeptide enzyme of 1048 amino
acids that forms a soluble dimer in solution. It contains a 55 kDa heme domain that is
fused via a short linker region to a 65 kDa reductase domain that houses FAD and FMN
flavins [9,10]. An interesting observation is that both domains exhibit structural similarities
to eukaryotic microsomal P450-containing systems. Specifically, there is the similarity of the
reductase domain to human cytochrome P450 reductuase (CPR) and of the heme domain
to the CYP2A and CYP4A fatty acid hydroxylase sub-families, while there is a lack of the
N-terminal encoded transmembrane anchor [11,12]. P450 BM3′s precise function in vivo is
not particularly well defined, but it is postulated that it plays a role in the detoxification of
xenobiotic lipids produced by plants [13,14].
The BM3 heme domain was among the first P450 crystal structures to be published,
shedding light on important motifs and residues within the protein (PDB code: 2HPD) [15].
BM3 exhibits a structural integrity conserved across the P450 superfamily, specifically
within the B’/C loop, the C- and E-helices, the E/F loop, the β5-sheet and the I-helix [16].
The heme domain of BM3 is relatively flexible and stable and contains the heme prosthetic
group necessary for catalysis [17]. BM3 also contains a long, hydrophobic, non-aromatic
substrate access channel, which is hypothesized to exist in a state of equilibrium between
the substrate-free and substrate-bound forms [18,19]. To date, the intact structure of BM3
has yet to be solved to a higher resolution, most likely due to the dynamic nature of the
reductase domain. Figure 1 illustrates the secondary structure of the BM3 heme domain in
complex with NPG (N-palmitoyl glycine), highlighting the key residues that play roles in
the substrate binding.
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Figure 1. The secondary structure and active site of NPG-bound WT BM3 heme domain (PDB: code 1JPZ). (A) Secondary 
structure of WT BM3 with key regions indicated. The heme group is shown as dark grey sticks with the iron in brown and 
NPG shown as ball and sticks in dark green. Regions that form the active site and substrate access channel are in multi-
colors. (B) The substrate access channel and active site of NPG-bound WT BM3. Heme and NPG are indicated as in panel 
A. All oxygens are in dark blue and nitrogens in red. Key residues involved in substrate binding are indicated in colors 
corresponding to their secondary structure regions in (A). Polar contacts of NPG with active site waters (red spheres) and 
residues Arg47, Tyr51 and Ala74 are indicated by yellow dashed lines. 
As mentioned above, BM3 catalysis is an electron-dependent process requiring two 
electrons delivered from the flavin-containing reductase domain that is attached to the 
heme domain via the linker region. This fusion yields a highly efficient system with sig-
nificantly increased activity relative to other monooxygenase P450s. This efficiency en-
hancement is attributed to the redox partner’s proximity to the heme iron. To date BM3 
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structure of WT BM3 with key regions indicated. T e heme group is shown as da k grey sticks with the ron in brown
and NPG shown as ball and sticks in dark green. Regions that form th active site and substrate access channel are n
multi-colors. (B) The substrate access channel and active site of NPG-bound WT BM3. Heme and NPG are indicated as in
panel A. All oxygens are in dark blue and nitrogens in red. Key residues involved in substrate binding are indicated in
colors corresponding to their secondary structure regions in (A). Polar contacts of NPG with active site waters (red spheres)
and residues Arg47, Tyr51 and Ala74 are indicated by yellow dashed lines.
As mentioned above, BM3 catalysis is an electron-dependent process requiring two
electrons delivered from the flavin-containing reductase domain that is attached to the
heme domain via the linker region. This fusion yields a highly efficient system with
significantly increased activity relative to other monooxygenase P450s. This efficiency
enhancement is attributed to the redox partner’s proximity to the heme iron. To date B 3
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has the highest reported catalytic activity of any known monooxygenase [20]. Electrons
are shuttled in a similar way to the process observed in the microsomal cytochrome P450
reductase (CPR or POR). This transfer starts with the NADPH hydride donation and is
followed by a series of FAD and FMN radical oxidations that lead to the electron transfer
to the heme domain as a part of the catalytic cycle as shown in Figure 2 [21,22]. The studies
with inactive heme and reductase domains suggest that the electrons are shuttled in an
intermolecular manner from the FMN in the reductase domain to the heme irons in either
heme domain [23]. This rapid electron transfer and malleable active site made BM3 an
attractive tool for biotechnological uses.
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dergoes a structural rearrangement to facilitate electron transfer to the heme iron (red square). 
There are several key residues in BM3 that play a critical role in the structure and 
function of both the heme and reductase domains, which over the years have made them 
attractive sites for mutagenesis. For example, to shift the specificity of BM3 to a structur-
ally diverse range of organic substrates or to investigate their structural and mechanistic 
properties. Figure 1 illustrates the interactions of several of these key residues in complex 
with NPG. Within the heme domain, Arg47 and Tyr51 sit at the mouth of the substrate 
access channel and form a hydrophilic binding region that holds fatty acid substrates in 
place via the carboxylate group [24]. Phe42 provides a ‘cap’ to the substrate access channel 
in the substrate-bound conformation that is important for catalytic efficiency [15,25]. 
Phe87 is located near the heme iron in the substrate access channel and plays a role in 
displacing the axial water molecule which triggers the active site reorganization. It has 
been demonstrated that Phe87 is a residue of great importance in controlling selectivity 
and specificity [24]. Other active site residues that have been identified as desirable mu-
tagenesis sites for substrate diversification are Ser72, Val78, Ala82 and Leu188, which play 
key roles in active site conformations [26]. Glu267 and Thr268 are conserved residues near 
the kink region of the I-helix (Figure 1, in yellow) and play key roles in proton delivery, 
oxygen activation and the stabilization of several catalytic cycle intermediates [27,28]. 
Ala264 is a residue on the I-helix that is postulated to draw the axially coordinated water 
Figure 2. Hypothetical dimeric BM3 electron transfer. The flavin c factors, FAD and FMN, facilitate electron transfer
from the reductase domain to th he e domain. FAD (yellow circles) transf rs elec rons to FMN (blue circles, which then
undergoes a structural rearrangement to facilitat electron transfer to t h me iron (red square).
There are several key residues in BM3 that play a critical role in the structure and
function of both the heme and reductase domains, which over the years have made them
attractive sites for t sis. r l , t s ift the specificity of BM3 to a structurally
diverse range of rganic substrates or to investigate t eir str ct ral a mechanistic
properties. Figure 1 illustrates the interactions of several of these key residues in complex
with P . ithin the heme domain, Arg47 and Tyr51 sit at the mouth of the substrate access
channel and form a hydrophilic binding region that holds fatty acid substrates in place via
the carboxylate group [24]. Phe42 provides a ‘cap’ to the substrate access channel in the
substrate-bound conformation that is important for catalytic efficiency [15,25]. Phe87 is
located near the heme iron in the substrate access channel and plays a role in displacing the
axial water molecule which triggers the active site reorganization. It has been demonstrated
that Phe87 is a residue of great importance in controlling selectivity and specificity [24].
Other active site residues that have been identified as desirable mutagenesis sites for
substrate diversification are Ser72, Val78, Ala82 and Leu188, which play key roles in active
site conformations [26]. Glu267 and Thr268 are conserved residues near the kink region of
the I-helix (Figure 1, in yellow) and play key roles in proton delivery, oxygen activation
and the stabilization of several catalytic cycle intermediates [27,28]. Ala264 is a residue on
the I-helix that is postulated to draw the axially coordinated water ligand from the binding
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site upon the I-helix rearrangement which is typical of substrate binding [29]. Whereas the
highly conserved Phe393 residue plays a key role in oxygen binding [30,31].
2. Wild Type BM3 and Pharmaceutical Metabolism
Whilst the wild-type enzyme has a comparatively narrow active site channel and
reluctantly binds small molecules that deviate from its hypothesized mid-chain-length,
fatty-acid native substrates, there are examples that show the metabolism of drug-like
precursors and pharmaceuticals. The studies on WT BM3 have shown that the enzyme
can accept substrates metabolized by human P450 isoforms, including catalyzing the
hydroxylation of structurally diverse compounds such as chlorzoxazone, aniline and
p-nitrophenol, the N-dealkylation of propranolol and the dehydrogenation of nifedipine.
The Vmax for all drugs was either comparable or higher than their human P450 counterparts
and it was found that WT BM3 exhibited product profiles similar to human CYP3A4 and
CYP2E1 [32]. Other examples of WT BM3 metabolizing drug-like compounds show a
relatively low activity in comparison to engineered variants designed through iterative
mutagenesis studies, including the vitamin A precursor β-ionone, 12-p-nitrophenoxy-
carboxylic acid and propylbenzene [33–35]. Figure 3 illustrates the modifications on
selected drug substrates by WT BM3.
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3. Engineering BM3 for Drug Metabolite Production
Due to the structural similarity of the BM3 heme domain to the human drug-metabolizing
P450s, coupled with the enzyme’s high catalytic efficiency and malleable active site, this
domain is an attractive target for mutagenesis studies with the aim of producing pharma-
ceutical metabolites. The following section aims to give a comprehensive overview of BM3
engineering for the production of valuable drug metabolites.
3.1. Key Promiscuous BM3 Variants and Library Screening
In early studies, BM3 was targeted as a potential bacterial homologue to many hu-
man drug-metabolizing P450s with the aim of shifting the specificity for the production
of large quantities of metabolites in an efficient and cost-effective manner. The iterative
mutagenesis studies on key active site residues have led to the identification of BM3 vari-
ants that exhibit substrate promiscuity. Some of the earliest directed evolution studies
on BM3 in Frances Arnold’s group led to the design of the promiscuous variants, 9-10A
and 139-3 (see Table 1 for details), which have since been carried forward in subsequent
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studies on pharmaceutical metabolite production for classes such as steroids, alkaloids,
and monosaccharides [36–38]. Promiscuous variants were designed based on the triple
mutant LVQ in Nico Vermeulen’s group through iterations of error-prone PCR and were
shown to exhibit activities up to 70-fold higher than human P450s for clozapine, diclofenac,
and acetaminophen [39]. M11 also showed a 200-fold increase in the turnover rate to-
wards dextromethorphan and 3,4-methylenedioxymethylamphetamine compared to WT
BM3 and a 90-fold increase compared to human CYP2D6 [40]. The triple mutant GVQ,
identified by saturation mutagenesis studies in the Urlacher and Commandeur groups,
was found to hydroxylate the omega positions of branched fatty acid derivatives. Further
studies demonstrated the ability of GVQ to metabolize structurally diverse human P450
substrates [41,42]. In the above examples of promiscuous variants, there is a clear trend
of the introduction of the same or similar point mutations which expand BM3′s catalytic
repertoire, including: the neutralization of the polar binding mouth of the active site
granting access to non-polar substrates (R47L/Y51F), the addition of polar residues to
counteract an overly non-polar environment (L188Q), the removal of Phe87 steric hindrance
(F87A/V/L/G) and active site reorganizations (A82L/F, A74E, V78L/F). These residues
are often utilized as initial mutagenesis targets in studies aiming to shift the specificity of
BM3 to non-natural substrates.
Table 1. Promiscuous BM3 variants and their corresponding drug substrates. Asterisks indicate where further point
mutations were introduced for metabolism.
BM3 Variant Point Mutations Substrates
LVQ [39] R47L/F87V/L188Q
clozapine [39], diclofenac [39], acetaminophen [39], omeprazole
[45], reservatrol * [46], polydatin [47,48], phloretin * [49,50],
cladosporin [51]
M01 [39] LVQ/E267V/G415S/G1049E
clozapine [39], diclofenac [39], acetaminophen [39], testosterone *
[52], noresthisterone * [53], methoxyresorufin [44],
ethoxyresorufin [44]
M02 [39] LVQ/L86I/N319T/A964V
clozapine [39], diclofenac [39], acetaminophen [39],
norandrostenedione [54], methoxyresorufin [44], ethoxyresorufin
[44], buspirone [44], amitriptyline [44], aripiprazole [44]
M05 [39] LVQ/F81I/E267V/G415S clozapine [39], diclofenac [39], acetaminophen [39],methoxyresorufin [44], ethoxyresorufin [44]
M11 [39] LVQ/E64G/F81I/E143G/E267V/G415S
clozapine [39], diclofenac [39], acetaminophen [39], Testosterone *
[52,55], norethisterone * [53,55], dextromethorphan [40],
nifedipine [40], midazolam [40],
3,4-methylenedioxymethylamphetamine [40], estradiol [14,56],
methoxyresorufin [44], ethoxyresorufin [44], buspirone [44],
duloxetine [44], thioridazine [44], ondansetron [44], imatinib [44],
omeprazole [44], rosiglitazone [44], paroxetine [44],
norethisterone [44], resveratrol [44], dihydrobenzophenone [44],
17α-ethinylestradiol [44], bisphenol A [44], diethylstilbestrol [44],
hexestrol [44], estriol [44], benzophenone-3 [44], aldrin [44],
testosterone [44], tramadol [44], imidazole [44], ketoconazole [44]
9-10A [36] R47C/V78A/K94I/P142S/T175I/A184V/F205C/S226R/H236Q/E252G/R255S/A290V/L353V verapamil [43], astemizole [43], LY294002 [43]
139-3 [38] V78A/H138Y/T175I/V178I/A184V/ H236Q/E252G/R255S/A290V/A295T/L353V androstenedione [57]
GVQ [41] A74G/F87V/L188Q testosterone [42], amodiaquine [42], dextromethorphan [42],acetaminophen [42], 3,4-methylenedioxymethylamphetamine [42]
Following the above studies, BM3 libraries were designed with the aim of reaching the
promiscuity of the major human drug-metabolizing P450s. One of the first reported libraries
was designed by the Arnold group and consisted of point mutations and homologue
chimeras. Several variants produced metabolites for verapamil, astemizole and LY294002.
A trend in variants evolved from 9-10A and point mutations at Phe87, Ala82 and Val78
exhibited the highest promiscuity and conversion rate. Bulkier substitutions at Ala82 and
Phe87 displayed higher conversions but decreased metabolite selectivity [36,43]. A library
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based on M11 was tested for the O-dealkylation activity of allyloxy-resorufins, with active
variants carried forward for affinity testing against several structurally diverse drugs. The
variants displayed differing degrees of affinity and selectivity to every drug, with key
metabolites produced for buspirone [40,44]. Table 1 gives an overview of the promiscuous
variants and their corresponding substrates.
3.2. Production of Human P450 Metabolites
Health governing bodies legally require a full drug metabolism and pharmacokinetic
profile of lead drug candidates for progression to phase I clinical trials [58]. This profile
requires the full structural elucidation of drug metabolites produced at 10% or more of
the level of the parent compound, as well as the determination of the in vivo effects [59].
Due to the relatively slow turnover rates of human P450s and the challenges that arise
with expressing and purifying membrane-bound proteins, it can be a laborious task to
produce metabolites in an easy and cost-efficient manner. BM3′s catalytic similarity to
major human P450 drug-metabolizing isoforms and its relative ease of use has made the
enzyme an attractive target for mutagenesis studies aiming to shift specificity towards the
production of human drug metabolites.
Previously, key variants were described that were designed for the expansion of BM3′s
catalytic repertoire for the metabolism of structurally diverse pharmaceuticals. With this
in mind, there have been several studies which attempted to design BM3 variants that
‘mimic’ the action of major human drug-metabolizing P450s. The CYP1A2 substrates,
phenacetin, ethoxyresorufin and methoxyresorufin, were selectively metabolized into the
human metabolites, acetaminophen and resorufin, respectively, by BM3 variants containing
combinations of mutations R47L, L86I, F87V and L188Q with an up to three-fold increase
in metabolism in comparison to CYP1A2 [60]. The variants containing L75R increase the
B’-helix flexibility and BM3’s ability to accept the typically acidic substrates of CYP2C9
and yield human metabolites of ibuprofen and naproxen [61]. A251G/Q307H also mimics
the actions of CYP2C9, selectively producing the human metabolites, 4-hydroxydiclofenac,
2-hydroxyibuprofen and 4-hydroxytolbutamide. Structural studies revealed that A251G
breaks a salt bridge between Asp251 and Lys221, increasing flexibility and triggering
structural rearrangements leading to the rotation of Phe87 [62,63]. A panel of variants that
aimed to mimic several isoforms of human drug-metabolizing P450s was designed that
led to the production of human drug metabolites for the isoforms CYP2C9 (diclofenac and
naproxen); CYP1A2 and CYP2E1 (chlorzoxazone); and CYP3A4 (testosterone, lidocaine
and amitriptyline) [64]. Whilst the above variants have the potential to be used as an
effective alternative tool for human metabolite production, there are limitations for their
use as a replacement for human P450s as they may not exhibit the same metabolic profile.
However, their promiscuity can be utilized for the production of human drug metabolites
that have been previously identified as crucial for pre-clinical testing.
BM3 variants are shown to target many drugs from the non-steroidal, anti-inflammatory
drug class (NSAIDs), for which human metabolites of naproxen, ibuprofen and diclofenac
were identified [39,61]. Further studies showed that CYP2C9 and CYP1A2 metabolites
of fenamic acids were produced with a high selectivity by BM3 variants and exhibited
higher turnover rates in comparison to human liver microsomes [65]. Several drugs in the
proton pump inhibitor class are metabolized by BM3 variants, yielding human metabo-
lites. The ‘gatekeeper’ variant, A82F/F87V, for which A82F ‘locks’ the active site in an
open conformation and F87V removes a steric hindrance from the active site, produces
human metabolites of omeprazole [26,45,66]. Other proton pump inhibitor metabolites are
illustrated in Figure 4 [66,67].
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Steroids are a major pharmaceutical class that are mainly metabolized by CYP3A iso-
forms. There are many examples in the literature of the production of human steroid
metabolites by variants of BM3. The mutations of interest include S72I, which is highly
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enantioselective for α-hydroxylations, and A82W, which appears to increase P450 coupling
efficiency [39,40,52,53,55,56]. Figure 5 illustrates in detail the metabolism of steroids to
produce both human and non-human metabolites. There are many more examples of hu-
man metabolite production by BM3 variants, which include, but are not limited to, anti-
cancer agents such as noscapine, beta blockers such as propranolol and antibiotics such as
flucloxacillin [49,50,68–73]. BM3-derived human metabolites are illustrated in Figure 4.
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The Arnold group designed some of the first reported BM3 chimeras, where the BM3
heme domain was combined with the homologues, CYP102A2 and CYP102A3, as part of a
promiscuous library which aimed to expand the catalytic repertoire for the metabolism
of structurally diverse compounds [43]. Attempts have also been made to harness the
BM3 reductase domain to facilitate the rapid electron transfer to typically slow drug-
metabolizing human P450s for the improved production of human metabolites. Constructs
have been designed that link the reductase domain to human P450s for the creation of a
self-sufficient, chimeric, human–bacterial, P450-containing system.
Human P450 chimeras display an advantage over BM3 variants for human metabolite
production as, not only is there a typical increase in the electron transfer to the human
P450 heme iron leading to increased metabolite production, but a self-sufficient soluble
chimera is also easier to work with. Additionally, the same human P450 metabolic profile
that is observed in vivo is also retained. This allows the chimeras to be used for metabo-
lite identification in pre-clinical studies. The fusion of the N-terminus CYP2E1 to the
C-terminus of the BM3 reductase domain resulted in an active system which showed the
formation of human p-nitrophenol and chlorzoxazone metabolites [74]. CYP2C9, CYP2C19
and CYP3A4 constructs were designed with a fusion to the reductase domain and were
expressed in E. coli to provide a self-sufficient P450 system without the addition of acces-
sory proteins, detergents or phospholipids for activity. All chimeras displayed a 15–30%
coupling efficiency and mimicked the WT BM3 dimeric formation in solution, as well as
displaying an activity with the FDA-approved probe substrates diclofenac, omeprazole and
erythromycin for each isoform, respectively. In addition, the turnover rate was comparable
to previously reported results for each human isoform in various reconstituted prepara-
tions [75]. The CYP3A4-BM3 reductase domain chimera further displayed an inhibition
potential with grapefruit juice, curcumin, and resveratrol, making it a desirable tool for the
studies of drug–drug interactions [76].
Further studies investigated the role of the heme domain-reductase domain connecting
loop on electron transfer efficiency by addition of glycine residues. The data showed that
the addition of five glycines increased the Vmax by two-fold for testosterone [77,78]. BM3’s
reductase domain was also fused to the bacterial P450 TxtE, which was shown to be crucial
in the thaxtomin pathway; a fusion with 14 amino acid linkers was found to reach a 100%
turnover by 8 h with a coupling efficiency 2.2 times higher than standalone TxtE [79].
The success of the BM3 reductase domain chimeras is in part due to the availability of
a naturally designed linker region which provides ease of construct design. The recent
attempts to design self-sufficient human P450-P450 reductase systems with human CPR
are yet to reach the electron transfer rates of BM3 chimeras [80].
3.3. Production of Clinically Relevant Pharmaceuticals and Related Precursors
3.3.1. Pharmaceutical Intermediate and Final Product Production
In current research there have been considerable efforts made towards pushing phar-
maceutical production, away from traditional organic synthesis routes and towards more
economically and environmentally sustainable biosynthesis pathways. There have been
several examples of biosynthetic routes in recent years where enzymes were utilized for the
production of valuable precursors and final products due to their relatively high yields, low
carbon footprint and ability to modify functional groups that were laborious to synthesize
chemically [81]. The presence of P450s in many natural product cascades led to the super-
family being of particular interest in the design of engineered biosynthetic pharmaceutical
cascades due to their selectivity and their ability to accept small organic compounds and
to perform selective hydroxylations which could be used as a molecular handle or for
late-stage functionalization [82].
There are several key examples of the BM3-mediated biotransformation of phar-
maceutical intermediates. The studies that target alkane-moieties, which are typically
cyclohexane derivatives, are of particular interest as specific hydroxylations can yield
crucial pharmaceutical precursors. The GVQ variant selectively metabolizes branched
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fatty acids at omega positions forming precursors to macrolide antibiotics [41]. WT BM3
stereoselectively hydroxylates α-isophorone to the vitamin E intermediate, 4-hydroxy-α-
isophorone, on a kilogram scale (detailed later in this review). Further studies showed that
the F87W/Y86F/L244A/V247L modification improved the selectivity by >98% [83,84]. The
metabolite (R)-4-hydroxy-iodotetralone, a key intermediate used in palladium-mediated
arylations and carbonylations, was produced by F87V at a 99% selectivity [85]. The
carotene precursor β-ionone can also be selectively hydroxylated by A74E/F87V/P386S
to 4-hydroxy-β-ionone [35].
BM3 variants have also been shown to target a range of benzene derivatives. The
production of vanillin from 3-methylanisole was achieved in a whole-cell E. coli system via
a three-step cascade using the BM3 variant A328L combined with mutated vanillyl alcohol
oxidase, albeit at a low conversion of 11.7% and a yield of 1.1% [86]. WT BM3 and the
selected variants also selectively hydroxylate the methyl-substituted benzene derivatives,
pseudocumene and mesitylene, to the phenolic building blocks used in the α-tocopherol
synthesis via quinolone intermediates. For example, the introduction of the point mu-
tation A330F increased the selectivity towards metabolite trimethylhydroquinolone to
75% [87,88]. The selective hydroxylation of various halogenated alkyl benzene derivatives
by R47L/Y51F/A330P yields key intermediates such as 2-chlorotoluene and 4-methyl-2-
ethylphenol with turnovers of 500 to 1600 min−1. Interestingly, ortho-substituted toluenes
displayed group migrations of the methyl group to meta-positions due to a hypothesized
epoxidation, ring opening and migration [89–91]. The stereoselective hydroxylation of
2-alkylated benzoic acid esters to produce phthalide (fungicide intermediates) and iso-
coumarin (serine protease inhibitors) derivatives was trialed on a preparative scale, which
led to the hydroxylation of 2-ethylbenzoate to enantiomers of 3-methylisobenzofuran [92].
The cyclopropanation of phenylacrylamide is the first step in a semi-synthetic route
to the antidepressant levomilinacipran. This cyclopropanation reaction was achieved by
replacing the axially heme iron coordinated cysteine with histidine (C400H) and by the
introduction of the point mutation T268A. In this variant the enzyme no longer proceeds
through the canonical mechanism utilizing an iron-oxo intermediate described earlier,
but now via a carbene transfer route [93]. A 48-variant library was screened for the
production of tetrahydroquinolone derivatives, yielding diverse products with varying
degrees of selectivity and functional group modifications. The specific mutations appeared
to control the type of biotransformation and led to the expansion beyond BM3’s typical
hydroxylations, including A328L which played a role in the metabolite dimer formation.
F87A/V, A328I and I263G favored C5 and C6 oxidations and also promoted metabolite
dimer formation, with F87 variants displaying activity towards aromatization. The range
of biotransformations performed by different variants in this study highlighted BM3’s role
as a selective multi-functional oxidase [94].
There are also key examples of utilizing BM3 variants for selective, late-stage oxy-
functionalization to yield clinically relevant pharmaceuticals. A late-stage hydroxylation
by P450s is advantageous for the addition of functional groups that are chemically la-
borious to synthesize and removes the need for protecting groups on typically reactive
hydroxyl groups. The preparative scale production of cyperenoic acid metabolites gives
high yields and high selectivity for products that display antiangiogenic-promoting ef-
fects [95]. Glucocorticosteroids are typically steroid-derived C16 alcohols, which require
selective hydroxylation; the combinations of BM3 variants at R47, Y51 and F87, displayed
selectivities of above 90% (Figure 6) [96]. M13 variant was utilized for the specific hydroxy-
lations to yield derivatives of existing pharmaceuticals that displayed enhanced medicinal
properties [71]. This variant was also employed for the production of the anticancer and
antibacterial agent esculetin on a preparative 3L scale, as well as for synthesizing the more
potent flavonoid antibacterial and anticancer agent, eriodictyol. The additional muta-
tions, I86C/P18W, led to the production of 3′-hydroxygenistein and 8-hydroxygenestein,
which displayed more potent pharmaceutical effects than the parent compound and the
angiogenesis inhibitor genistein [97–99].
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3.3.2. 3 in Se i-Synthetic o tes an iosynthetic asca e roduction of
Pharmaceuticals
As demonstrated previously, BM3 and its extensive catalytic repertoire make the
enzyme an attractive biotechnological tool for the incorporation into semi-synthetic routes
and biosynthetic enzyme cascades for the production of clinically relevant pharmaceuticals.
There are many examples of utilizing BM3 for typically chemically laborious hydrox-
ylations; as either a molecular handle for functional group additions or for late-stage
diversification. The cascade synthesis of the antifungal putaminoxins, B and D, utilized
A74G/L188Q in tandem with alcohol dehydrogenase (ADH) for hydroxylation and allylic
alcohol formation, which was a key step in macrolactone formation [100].
Another example of incorporating BM3 into a semi-synthetic route is the synthesis
of nigelladine A. Starting with 3-isopropylcyclohexenone, a chemical synthesis route
to the intermediate tricycle was achieved with a singular allylic oxidation required to
achieve nigelladine A. The final oxidation and imine bond formation was performed by
L75A/L181A and ADH at a 43% yield [101]. F87V and WT BM3, respectively, can selectively
epoxidate arachidonic and linoleic acid to produce 14-(S)-,15-(R)-epoxyeicosatrienoic acid
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and leukotoxin B, with approximately a 45% conversion on a mg scale, which was carried
forward to produce 14-(R)-,15-(S)-epoxyeicosatrienoic acid [102].
The production of the anti-cancer and antimicrobial meroterpenoids was achieved via
the design of modular retrosynthetic pathways. The addition of molecular handle hydroxyl
groups was achieved by variants related to 1857 (V78A/A82G/F87V/P142S/T175I/A184V/-
F205C/S226R/H236Q/E252G/R255S/A290V/L353V) [103,104]. The selective 3-hydroxylation
of sclareolide, an antifungal precursor to arisugacin F and phenylpyropene C, gave an
80–90% conversion and a 60–70% yield for 1857/V328A. A 62% yield was achieved by
1857/V328A/L75A for the oxidation of a tricyclic intermediate at the C3 position, form-
ing a key intermediate for further chemical modification, ultimately yielding either chevalone
or stypodiol [104].
The synthesis of L-tyrosine derivatives, which were intermediates to anticancer
drugs such as saframycin A, was achieved via the R47S/Y51W/I401M-mediated ortho-
hydroxylation of monosubstituted benzenes in a one-pot, two-step synthesis. The sub-
sequent addition of pyruvate and ammonia, utilizing a variant of tyrosine phenol lyase,
led to hydroxy-derivatives of tyrosine, with the ortho-hydroxylation leading to tyrosine’s
distinctive para-phenol [105]. On a preparative scale, low-to-medium turnover rates were
observed with a selectivity above 50% and enantiomeric excesses of >97% for all deriva-
tives [106]. BM3 could also be used as a multi-step mixed-function oxidase. A two-step
hydroxylation of the macrocyclic diterpenoid β-cembrenediol by BM3 variants yielded
(9S,10S)-β-cembrenetetraol, displaying up to 90% enantiomeric excess [107]. Figure 6
illustrates key examples of BM3 in enzyme cascades.
3.4. Utilizing BM3 for Production of Emerging Pharmaceuticals
The research into the biosynthetic production of pharmaceuticals has led to harnessing
and engineering enzymes from natural product cascades for a generation of emerging
pharmaceuticals to explore chemical space that is difficult to reach by means of chemical
synthesis [108]. As detailed previously, the catalytic repertoire of BM3 extends beyond
what is typically available in traditional synthesis routes, and there are many examples
of the production of analogues resulting from BM3-mediated oxidation modifications not
previously observed. This section gives an overview of the utilization of BM3 for the
production of emerging pharmaceuticals and is summarized in Figure 7.
Previously, the production of BM3 and human steroid metabolites was discussed.
There were also extensive studies into the hydroxylation of steroid positions that were
difficult to reach for late-stage diversification or as molecular handles. The variant, 139-3
(see Table 1), hydroxylates androstenedione at the challenging 1α-position. This interesting
reaction is postulated to be caused by Arg379 which is thought to play a role in active site
orientation [58]. Steroidal C6β- and C7β-alcohols are shown to display neuroprotective
and anti-inflammatory properties but are difficult to chemically oxidate. Several variants
are shown to hydroxylate at these positions with high selectivities [109,110]. Table 2 gives
an overview of BM3-mediated steroid hydroxylation.
Terpenoids are attractive targets for BM3 diversification. The sesquiterpene lactone
parthenolide was previously shown to possess anti-cancer activity but requires the im-
provement of pharmacokinetic properties. The BM3-mediated addition of hydroxyl groups
as molecular handles at the C9- and C14- allowed the addition of the aromatic functional
groups and led to the discovery of potent parthenolide-based antileukemic agents [111,112].
Studies also aimed to diversify meroterpenoids; selective hydroxylations at the C2-positions
of ent-kaurenoic acid and a derivative of isosteviol led to the production of cochleareine
and spiramilactone C derivatives [113].
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The diversification of the flavonoid class of pharmaceuticals was explored using vari-
ants of BM3 as they displayed a wide range of medicinal properties. The flavanone deriva-
tive, s chalcone and isoflavone, were hydroxylated in multiple positions by F87V, with
dihydroxyflavanone derivatives displaying the highest IC50 values for antioxidant activity
via testing the lipid peroxidation in rat brain homogenate [114]. Further studies showed
that the antioxidant daidzein was turned over by Y51L/F87A to 3-hydroxydaidzein, a
compound with more potent effects [115].
The diversification of building blocks for pharmaceuticals is also of interest as the
molecular handle of the hydroxyl groups can lead to a wide range of new analogues. The
sulfoxidation of 1-thioch oman-4-ones can lead to building blocks of pharmaceutical inter-
est with pote tial anti-cancer properties. BM3 was engineered for (S)- and (R)-s lfoxidation
as a r placement to chiral metal catalysts with high selectivities for p cific variants dis-
played [116]. Other key examples of the BM3-mediated diversificat on of pharmaceu als
include the st reosel ctive hydroxylation of eleuthoside intermediates, related to the emerg-
ing anti-cancer agent, eleuthorobin.
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Table 2. BM3-mediated steroid metabolism. Only sites of modification are identified. * Indicates human CYP3A metabolite.
Conv, conversion; sel, selectivity; ee, enantiomeric excess.
Steroid Structure OH-Position Variant Parameters
Testosterone
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From a panel of BM3 variants including GVQ, the hydroxylation of cyclohexane-
based moieties produced a range of oxidized metabolites with high conversion rates and
varying degrees of selectivity for several positions. Phe87 variants displayed the ability
to further oxidize alcohols to aldehydes with a high regioselectivity and preparative scale
reactions showed the ability of BM3 to produce lead drug candidates under scaled-up
conditions [117]. The late-stage functionalization of the antimalarial compound cladosporin
by LVQ led to the production of ketone derivatives that expressed some degree of potency
in the micromolar range against P. falciparum [51]. Late-stage oxidations can present a
challenge with selectivity and the production of unwanted by-products. An attempt to
solve this issue was trialed with vabicaserin with the addition of a protecting group to
‘steer’ the oxidation site of BM3 variants; an analogue was metabolized by F87V to yield
several metabolites with hydroxylations at various positions before the cleavage of the
protecting groups [118].
4. Stretching the Use of BM3
In addition to the extensive studies on engineering the BM3 heme domain to expand
the catalytic repertoire, there are also studies based on other engineering strategies for the
production of valuable pharmaceuticals. This section aims to give an overview on how
BM3 can be used outside of the traditional directed evolution approaches and how it can
be utilized for real-world applications.
4.1. Decoy Molecules
Decoy molecules are small molecules that co-occupy active sites without metabolism
or inhibition and ‘activate’ enzymes without the need for mutagenesis by occupying space
in the active site. The addition of the decoy molecules allows active sites to accept smaller
substrates, for example in the WT BM3 heme domain. With the aid of semi-synthetic
decoy molecules based on amino acid derivatives, WT BM3 can catalyze the oxidation
of benzene to the pharmaceutical precursor phenol, a key intermediate in the synthetic
routes of drugs such as aspirin [119,120]. C7-L-Proline-L-Phenylalanine increased the
turnover of benzene by WT BM3 from negligible rates to 259 min−1, whilst the addition of
N-heptyl-l-prolyl-l-phenylalanine led to a phenol yield of 59% [120]. C4- to C8-chain length
fatty acids were also utilized for the enantioselective hydroxylation of the pharmaceutical
precursors styrene, ethylbenzene and thioanisole. The results showed that the C5–C7 chain
length displayed a balance of increased turnover and selectivity; (S)-styrene oxide was
produced with similar selectivities for all decoy molecules with hexanoic acid displaying
the highest turnover (334 min−1). Ethylbenzene heptanoic acid displayed the best turnover
(28 min−1) and selectivity (68%) for (R)-phenylethan-1-ol [121].
4.2. Industrial and Preparative Scale-up
The biocatalytic production of valuable drug metabolites on an industrial scale is
desirable, as these processes are often cheaper, greener, and more efficient with higher
purity and yields. There are several examples of scaling up BM3 for preparative (mg)
and industrial (g to kg) metabolite production, and there are numerous examples of
commercialized production. One of the most notable examples from recent years is the
stereoselective hydroxylation of α-isophorone to the carotenoid and the vitamin E precursor
4-hydroxy-α-isophorone by WT BM3 on a kilogram scale. WT BM3 was co-expressed with
glucose dehydrogenase in E. coli and in 1000 L reactors, providing a yield of 0.95 kg of
purified oxy-metabolite and a productivity of 1000 mg/L/h. The success of this whole-cell
scale-up paves the way for future industrial metabolite production utilizing BM3 and
related variants [84]. The production of the anti-tumor drug, desmethyl-colchicine, from
colchicine on a 70 L bioreactor scale was achieved by E. coli whole-cell reactions expressing
WT BM3; ~80% conversion was achieved in 48 h with a productivity of 6.62 mg/L/h,
and a maximum yield of 5.96 g/L [122]. Throughout this review there are examples of
the preparative scale-up of BM3-mediated metabolite production; this includes but is not
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limited to 16-β-hydroxy-norandrostenedione, 3-methylbenzofuran, C7-hydroxy-cyperenoic
acid, esculetin and leukotoxin B [54,92,95,97,102].
4.3. Medicinal Usage of BM3
Future emerging therapies are exploring the use of enzymes as in vivo alternatives
or enhancements to existing treatments, as they can be harnessed for uses such as in vivo
imaging and site-specific, pro-drug metabolism [123]. A key example of utilizing BM3
for in vivo imaging includes the detection of the neurotransmitter dopamine using the
BM3 heme domain as a contrast agent for magnetic resonance imaging. The dopamine
binding to sites near the paramagnetic heme iron of evolved BM3 variants decreases signal
enhancement and a shift in optical absorbance is also observed. The release of dopamine
was imaged in PC12 cells and the brains of live animals [124]. Further work led to the
development of the evolved BM3 sensors for dopamine (T268A/I263A/T438V/A328G, KD
1.3 µM) and serotonin (F87L/T438L/T268S/L437Q, KD 700 nM) which were both utilized
for the neurotransmitter release quantitation in vitro [125].
Recent studies on the in vivo therapeutic delivery systems encompassed BM3 as part
of bionanoparticle systems, with the purpose of harnessing the metabolism for therapeutic
gain. Several drugs require activation by the P450 mediated metabolism; however, once
activated, the bioavailability may significantly decrease before reaching the therapeutic
target due to polar metabolites typically exhibiting shorter half-lives. Delivering BM3
variants to therapeutic sites has been explored with the aim of increasing prodrug potency.
The activation of the anticancer prodrugs, cyclophosphamide and ifosfamide, by
M11 and M11 L437S, identified in previous studies, were found to be highly active for
4-hydroxylation of both prodrugs; M11 displayed catalytic efficiencies of ~10,000 and
~1350 mol product/min/mol CYP/mM for cyclophosphamide and ifosfamide, respec-
tively. The extracellular bioactivation led to a cytotoxicity in U2OS cells [126]. The biotrans-
formation of the endocrine disruptor compounds such as bisphenol A, nonylphenol and
triclosan by P450s was crucial to counteract their harmful effects.
A bionanoreactor encompassing the capsid of the bacteriophage P22 with the peroxy-
genase variant 21B3 (identified in previous studies), functionalized with glucose oxidase
on the outside as part of an electron transfer system, led to a turnover rate of approxi-
mately half of the free BM3, making the system a viable route for therapeutic detoxifica-
tion [127,128]. The usage of BM3 in a bionanoreactor as part of drug delivery was shown
when encompassing F87A and glucose oxidase in a nanoreactor crosslinked with human
serum albumin, with the aim of improving tamoxifen efficacy. The selective delivery of the
nanoreactor to MCF-7 cells was observed showing a triple effect of depleting glucose levels,
an antioxidant effect from the glucose–oxidase byproduct, hydrogen peroxide, and the
metabolism of prodrug tamoxifen into its active metabolite by F87A. MTT assays showed
that the co-administration of tamoxifen and the bionanoreactor decreased cell viability
from ~45% to ~10% when compared to the drug alone [129].
5. Summary, Conclusions and Outlook
In terms of directed evolution, BM3 is a key focal point and one of the best examples to
highlight the advantages of the biosynthetic production of valuable small molecules. The
enzyme’s ease of production, catalytic repertoire and ability to perform specific oxidations
that are typically chemically laborious makes BM3 one of the most attractive biotechnologi-
cal tools for current and future metabolite production. Several high-activity, promiscuous
variants were developed using a range of engineering strategies. The comparison of these
studies, in conjunction with extensive active site investigations, has allowed researchers to
pinpoint crucial key residues that play pivotal roles in structurally diverse substrate accep-
tance, enantio- and regioselectivity, metabolic rates and electron transfer. The malleable
nature of the BM3 active site has, therefore, led to the publication of hundreds of papers
investigating the metabolite production of a vast range of structurally diverse compounds,
of which a significant number have targeted pharmaceuticals. The similarities between
Int. J. Mol. Sci. 2021, 22, 11380 18 of 23
major human drug-metabolizing P450s and BM3’s metabolic profiles led to much research
focusing on designing human P450 ‘mimics’, or selective variants for the production of
human P450 metabolites, as an attractive alternative to the relatively slower and membrane-
bound human isoforms. Whilst the BM3 heme domain variants are unlikely to be used as
a replacement for human P450s in the pre-clinical metabolic profiling of emerging phar-
maceuticals, advances such as the BM3 reductase-human P450 heme chimeras show that
there is a potential for using the BM3 flavin domain in pharmacokinetic studies. There
are also many examples which show that BM3 has the potential to be harnessed in the
production of the pharmaceutical intermediates and final products. The enzyme’s ability
to specifically oxidize a range of positions in structurally diverse compound classes with
a high selectivity and high yields has not only been demonstrated in the literature, but
on preparative and industrial scales which has led to key examples of the commercial
production of pharmaceutical intermediates. Its utility as a mixed function oxidase and
ease of expression in whole-cell microorganism systems has led to the addition of several
key variants to biosynthetic cascades, which are arguably the future of pharmaceutical
production. In the current climate, BM3 has the potential to be used as a key biotechnologi-
cal tool, allowing the shift away from traditional organic synthesis routes towards more
sustainable biosynthetic means of production.
BM3 also has the ability to diversify existing and new pharmaceutical libraries, as
its catalytic abilities allow oxidized functional groups to be utilized as molecular handles
or for late-stage diversification. Key examples in the literature show the BM3-mediated
production of more potent analogues of several emerging pharmaceuticals, solidifying
its future role in the enzyme-mediated expansion of the pharmaceutical chemical space
that organic synthesis cannot reach. BM3 has also been shown to be a valuable tool
in emerging medicinal therapeutics, where the delivery of selected variants to target
sites in the bionanoreactors led to successes in targeting different medical issues, such as
in vivo imaging and increasing drug efficacy. The literature is filled with examples of BM3
metabolite production with a wide range of purposes, and this promiscuous bacterial P450
will most certainly continue to appear in future academic and industrial settings.
Author Contributions: Writing—original draft preparation, S.T.; writing—review and editing, L.N.J.,
H.M.G., K.J.M.; supervision, A.W.M.; funding acquisition, A.W.M. All authors have read and agreed
to the published version of the manuscript.
Funding: This research was funded by the UKRI Biotechnology and Biological Sciences Research
Council, grant number BB/M011208/1.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Roberts, A.A.; Ryan, K.S.; Moore, B.S.; Gulder, T.A.M. Total (Bio)synthesis: Strategies of nature and of chemists. Top. Curr. Chem.
2010, 297, 149.
2. Rupasinghe, S.; Schuler, M.A.; Kagawa, N.; Yuan, H.; Lei, L.; Zhao, B.; Kelly, S.L.; Waterman, M.R.; Lamb, D.C. The cytochrome
P450 gene family CYP157 does not contain EXXR in the K-helix reducing the absolute Conserved P450 residues to a single
cysteine. FEBS Lett. 2006, 580, 6338–6342. [CrossRef]
3. Guengerich, F.P.; Macdonald, T.L. Chemical mechanisms of catalysis by cytochromes P-450: A unified view. Acc. Chem. Res. 1984,
17, 9–16. [CrossRef]
4. Whitehouse, C.J.C.; Bell, S.G.; Wong, L.-L. P450 BM3 (CYP102A1): Connecting the dots. Chem. Soc. Rev. 2012, 41, 1218–1260.
[CrossRef] [PubMed]
5. Iyanagi, T. Molecular mechanism of phase I and phase II drug-metabolizing enzymes: Implications for detoxification. Int. Rev.
Cytol. 2007, 260, 35–112. [PubMed]
6. Miura, Y.; Fulco, A.J. (ω-2) Hydroxylation of fatty acids by a soluble system from Bacillus megaterium. J. Biol. Chem. 1974, 249,
1880–1888. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 11380 19 of 23
7. Miura, Y.; Fulco, A.J. ω-1, ω-2 and ω-3 hydroxylation of long-chain fatty acids, amides and alcohols by a soluble enzyme system
from Bacillus megaterium. Biochim. Biophys. Acta 1975, 388, 305–317. [CrossRef]
8. Hare, R.S.; Fulco, A.J. Carbon monoxide and hydroxymercuribenzoate sensitivity of a fatty acid (ω-2) hydroxylase from Bacillus
megaterium. Biochem. Biophys. Res. Commun. 1975, 65, 665–672. [CrossRef]
9. Narhi, L.O.; Fulco, A.J. Identification and Characterization of two functional domains in cytochrome P-450BM-3, a catalytically
self-sufficient monooxygenase induced by barbiturates in Bacillus megaterium. J. Biol. Chem. 1987, 262, 6683–6690. [CrossRef]
10. Narhi, L.O.; Fulco, A.J. Characterization of a catalytically self-sufficient 119,000-dalton Cytochrome P-450 monooxygenase
induced by barbiturates in Bacillus megaterium. J. Biol. Chem. 1986, 261, 7160–7169. [CrossRef]
11. Porter, T.D. An unusual yet strongly conserved flavoprotein reductase in bacteria and mammals. Trends Biochem. Sci. 1991, 16,
154–158. [CrossRef]
12. Lewis, D.F.V.; Watson, E.; Lake, B.G. Evolution of the cytochrome P450 superfamily: Sequence alignments and pharmacogenetics.
Mutat. Res. 1998, 410, 245–270. [CrossRef]
13. Fulco, A.J. Chain elongation, 20hydroxylation, and decarboxylation of long chain fatty acids by yeast. J. Biol. Chem. 1967, 242,
3608–3613. [CrossRef]
14. English, N.; Hughes, V.; Wolf, C.R. Common pathways of cytochrome P450 gene regulation by peroxisome proliferators and
barbiturates in Bacillus megaterium ATCC14581. J. Biol. Chem. 1994, 269, 26836–26841. [CrossRef]
15. Ravichandran, K.G.; Boddupalli, S.S.; Hasemann, C.A.; Peterson, J.A.; Deisenhofer, J. Crystal structure of hemoprotein domain of
P450BM-3, a prototype for microsomal P450′s. Science 1993, 261, 731–736. [CrossRef]
16. Hasemann, C.A.; Kurumbail, R.G.; Boddupalli, S.S.; Peterson, J.A.; Deisenhofer, J. Structure and function of cytochromes P450:
A comparative analysis of three crystal structures. Structure 1995, 3, 41–62. [CrossRef]
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